JP2019530440A5 - - Google Patents

Download PDF

Info

Publication number
JP2019530440A5
JP2019530440A5 JP2019512186A JP2019512186A JP2019530440A5 JP 2019530440 A5 JP2019530440 A5 JP 2019530440A5 JP 2019512186 A JP2019512186 A JP 2019512186A JP 2019512186 A JP2019512186 A JP 2019512186A JP 2019530440 A5 JP2019530440 A5 JP 2019530440A5
Authority
JP
Japan
Prior art keywords
seq
binding protein
chain variable
variable region
chimeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019512186A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019530440A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2017/055281 external-priority patent/WO2018042385A2/en
Publication of JP2019530440A publication Critical patent/JP2019530440A/ja
Publication of JP2019530440A5 publication Critical patent/JP2019530440A5/ja
Withdrawn legal-status Critical Current

Links

JP2019512186A 2016-09-02 2017-09-01 インターロイキン６受容体α結合単鎖可変断片を含む方法および組成物 Withdrawn JP2019530440A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662383237P 2016-09-02 2016-09-02
US62/383,237 2016-09-02
US201662440991P 2016-12-30 2016-12-30
US62/440,991 2016-12-30
US201762443509P 2017-01-06 2017-01-06
US62/443,509 2017-01-06
PCT/IB2017/055281 WO2018042385A2 (en) 2016-09-02 2017-09-01 Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments

Publications (2)

Publication Number Publication Date
JP2019530440A JP2019530440A (ja) 2019-10-24
JP2019530440A5 true JP2019530440A5 (cg-RX-API-DMAC7.html) 2020-10-08

Family

ID=61300216

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019512186A Withdrawn JP2019530440A (ja) 2016-09-02 2017-09-01 インターロイキン６受容体α結合単鎖可変断片を含む方法および組成物

Country Status (8)

Country Link
US (2) US11701384B2 (cg-RX-API-DMAC7.html)
EP (1) EP3506943B1 (cg-RX-API-DMAC7.html)
JP (1) JP2019530440A (cg-RX-API-DMAC7.html)
KR (1) KR20190057308A (cg-RX-API-DMAC7.html)
CN (1) CN109963590B (cg-RX-API-DMAC7.html)
AU (1) AU2017319702B2 (cg-RX-API-DMAC7.html)
CA (1) CA3039136A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018042385A2 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11274144B2 (en) 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
EP4400516A1 (en) 2014-12-15 2024-07-17 The Regents of the University of California Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
HK1255383A1 (zh) 2015-07-31 2019-08-16 The Research Institute At Nationwide Children's Hospital 去除生物膜的肽及抗體
CN108148863B (zh) * 2016-12-05 2019-12-17 上海优卡迪生物医药科技有限公司 一种封闭il6r的用于缓解crs的car-t转基因载体及其构建方法和应用
JP7514621B2 (ja) 2017-01-04 2024-07-11 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル Ｄｎａｂｉｉワクチンおよび強化された活性を有する抗体
AU2018206560B9 (en) 2017-01-04 2025-04-03 Research Institute At Nationwide Children's Hospital Antibody fragments for the treatment of biofilm-related disorders
EP3765154A4 (en) 2018-03-14 2021-11-24 Celledit LLC MODIFICATION OF IMMUNE CELLS TO REDUCE TOXICITY AND THEIR USES IN ADOPTIVE CELL THERAPY
WO2019178085A1 (en) * 2018-03-14 2019-09-19 Seattle Children's Hospital (dba Seattle Children's Research Institute) Il-13 receptor alpha 2 targeted, zetakine directed t cell immunotherapy
WO2020072993A1 (en) 2018-10-05 2020-04-09 Research Institute At Nationwide Children's Hospital Hmgb1 protein derivatives for the removal of biofilms cross-reference to related application
CA3127669A1 (en) * 2019-01-07 2020-07-16 Hunan Siweikang Therapeutics Co. Ltd Modified immune cells co-expressing chimeric antigen receptor and il-6 antagonist for reducing toxicity and uses thereof in adoptive cell therapy
JP2022534513A (ja) * 2019-05-31 2022-08-01 ザ・ジョンズ・ホプキンス・ユニバーシティー がん細胞遊走を阻害するためのＩＬ－６Ｒα／ＩＬ－８Ｒ二重特異性結合剤
EP3976644A4 (en) 2019-05-31 2022-12-14 The Johns Hopkins University BI-SPECIFIC LIAISONS
US12209118B2 (en) * 2019-07-08 2025-01-28 Research Institute At Nationwide Children's Hospital Antibody compositions for disrupting biofilms
EP4543923A1 (en) * 2022-06-22 2025-04-30 Juno Therapeutics, Inc. Treatment methods for second line therapy of cd19-targeted car t cells

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8200523A (nl) 1982-02-11 1983-09-01 Univ Leiden Werkwijze voor het in vitro transformeren van planteprotoplasten met plasmide-dna.
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4879236A (en) 1984-05-16 1989-11-07 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
US5670373A (en) 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
US4952500A (en) 1988-02-01 1990-08-28 University Of Georgia Research Foundation, Inc. Cloning systems for Rhodococcus and related bacteria
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5302523A (en) 1989-06-21 1994-04-12 Zeneca Limited Transformation of plant cells
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US7705215B1 (en) 1990-04-17 2010-04-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5550318A (en) 1990-04-17 1996-08-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
DE10399023I2 (de) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
US5322783A (en) 1989-10-17 1994-06-21 Pioneer Hi-Bred International, Inc. Soybean transformation by microparticle bombardment
US5484956A (en) 1990-01-22 1996-01-16 Dekalb Genetics Corporation Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US5543293A (en) 1990-06-11 1996-08-06 Nexstar Pharmaceuticals, Inc. DNA ligands of thrombin
US5503978A (en) 1990-06-11 1996-04-02 University Research Corporation Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
HU218140B (hu) 1991-04-25 2000-06-28 Chugai Seiyaku Kabushiki Kaisha Humán interleukin-6-receptorral szembeni átalakított humán antitest
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5138941A (en) 1991-06-28 1992-08-18 Strauss Frederick J Wooden crusher for recyclable metal cans
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5610042A (en) 1991-10-07 1997-03-11 Ciba-Geigy Corporation Methods for stable transformation of wheat
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
EP1983056A1 (en) 1992-07-07 2008-10-22 Japan Tobacco Inc. Method for transforming monocotyledons
US5702932A (en) 1992-07-20 1997-12-30 University Of Florida Microinjection methods to transform arthropods with exogenous DNA
HUT70467A (en) 1992-07-27 1995-10-30 Pioneer Hi Bred Int An improved method of agrobactenium-mediated transformation of cultvred soyhean cells
GB9222888D0 (en) 1992-10-30 1992-12-16 British Tech Group Tomography
AU5670194A (en) * 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
US5656610A (en) 1994-06-21 1997-08-12 University Of Southern California Producing a protein in a mammal by injection of a DNA-sequence into the tongue
US5871986A (en) 1994-09-23 1999-02-16 The General Hospital Corporation Use of a baculovirus to express and exogenous gene in a mammalian cell
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5631146A (en) 1995-01-19 1997-05-20 The General Hospital Corporation DNA aptamers and catalysts that bind adenosine or adenosine-5'-phosphates and methods for isolation thereof
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
US5945100A (en) 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
US5981274A (en) 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
US6132722A (en) 1997-05-07 2000-10-17 Bristol-Myers Squibb Company Recombinant antibody-enzyme fusion proteins
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
WO1999019466A2 (en) 1997-10-14 1999-04-22 Darwin Molecular Corporation Thymidine kinase mutants and fusion proteins having thymidine kinase and guanylate kinase activities
US5994624A (en) 1997-10-20 1999-11-30 Cotton Incorporated In planta method for the production of transgenic plants
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
AU2001298053A1 (en) 2001-09-27 2003-04-14 Pieris Proteolab Ag Muteins of apolipoprotein D
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
US7066469B2 (en) 2002-08-06 2006-06-27 University of Kentucky Research Foundation Board of Supervisors of Louisiana State University Seal assembly for machinery housing
US20040043949A1 (en) 2002-08-30 2004-03-04 Christopher Richardson Therapeutic system targeting pathogen proteases and uses thereof
UA80296C2 (en) 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
WO2004085611A2 (en) 2003-03-21 2004-10-07 The Research Foundation Of State University Of New York Model for mutually exclusive domain folding molecular switch
JP2007521315A (ja) 2003-08-01 2007-08-02 アムジェン インコーポレイテッド 結晶性腫瘍壊死因子レセプター２ポリペプチド
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
BRPI0508761A (pt) 2004-03-31 2007-08-14 Genentech Inc anticorpo humanizado, composição que compreende um anticorpo humanizado, ácido nucléico isolado, vetor, célula hospedeira, processo de produção de anticorpo humanizado, método de tratamento de disfunção tgf-beta, método de detecção de tgf-beta, artigo industrializado e método de tratamento de cáncer
JPWO2006046661A1 (ja) 2004-10-28 2008-05-22 国立大学法人大阪大学 インターロイキン−６阻害剤
US7892827B2 (en) 2004-11-26 2011-02-22 Pieris Ag Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
PL1850873T3 (pl) 2005-02-08 2019-06-28 Genzyme Corporation Przeciwciała przeciwko tgfbeta
US20090068158A1 (en) 2005-12-09 2009-03-12 Medin Jeffrey A Thymidylate kinase mutants and uses thereof
JP2009519977A (ja) 2005-12-16 2009-05-21 アルコン，インコーポレイテッド Ａｌｋ５調整剤を用いた眼内圧のコントロール
TWI440469B (zh) * 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
KR101829073B1 (ko) 2009-06-26 2018-02-13 아이2 파마슈티컬스, 인크. 대리 경쇄의 발현
ES2686424T5 (es) 2010-05-04 2023-03-27 Yeda Res & Dev Inmunoterapia con células alogénicas redireccionadas
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
WO2012064627A2 (en) 2010-11-08 2012-05-18 Genentech, Inc. Subcutaneously administered anti-il-6 receptor antibody
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US20130071414A1 (en) 2011-04-27 2013-03-21 Gianpietro Dotti Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
EP3594245A1 (en) 2012-02-13 2020-01-15 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
US20130280220A1 (en) 2012-04-20 2013-10-24 Nabil Ahmed Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
EP4029937A1 (en) 2012-10-04 2022-07-20 Research Development Foundation Serine protease molecules and therapies
EP2730289A1 (en) 2012-11-07 2014-05-14 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Novel immunoproteases
HUE041499T2 (hu) 2012-11-21 2019-05-28 Janssen Biotech Inc Bispecifikus EGFR/C-MET-ellenanyagok
AU2014249051B2 (en) 2013-03-11 2018-02-15 Genzyme Corporation Engineered anti-TGF-beta antibodies and antigen-binding fragments
EP3626748A1 (en) 2014-01-13 2020-03-25 Stephen J. Forman Chimeric antigen receptors (cars) having mutations in the fc spacer region and methods for their use
KR102157924B1 (ko) 2014-02-14 2020-10-26 셀렉티스 면역 세포들 및 병리 세포들 둘 다에 존재하는 항원을 타겟팅하기 위하여 조작된 면역치료용 세포들
CA2939411A1 (en) 2014-02-27 2015-09-03 Ucl Business Plc Ligand
AU2015343013B2 (en) 2014-11-05 2020-07-16 Board Of Regents, The University Of Texas System Gene modified immune effector cells and engineered cells for expansion of immune effector cells
AU2015360845B2 (en) 2014-12-12 2020-11-26 2Seventy Bio, Inc. BCMA chimeric antigen receptors
WO2016130598A1 (en) 2015-02-09 2016-08-18 University Of Florida Research Foundation, Inc. Bi-specific chimeric antigen receptor and uses thereof
CN108884155B (zh) 2015-10-30 2022-12-06 加利福尼亚大学董事会 转化生长因子-β应答多肽及其使用方法
EP3383892B1 (en) 2015-12-03 2022-12-21 Juno Therapeutics, Inc. Modified chimeric receptors and related compositions and methods
EP3436070A4 (en) 2016-03-29 2019-11-27 University of Southern California AGAINST CANCER, CHIMERIC ANTIGEN RECEPTORS
CN105837693A (zh) 2016-05-30 2016-08-10 李斯文 一种基于bcma的抗原嵌合受体及其制备方法和应用
US20200283534A1 (en) 2016-06-24 2020-09-10 iCell Gene Therapeuticics LLC CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF
IL266892B2 (en) 2016-12-02 2025-10-01 Univ Southern California Artificial immune receptors and methods of using them
CN108148863B (zh) * 2016-12-05 2019-12-17 上海优卡迪生物医药科技有限公司 一种封闭il6r的用于缓解crs的car-t转基因载体及其构建方法和应用
US12275787B2 (en) 2017-06-21 2025-04-15 Icell Gene Therapeutics Llc Chimeric antigen receptors (CARs), compositions and methods thereof

Similar Documents

Publication Publication Date Title
JP2019530440A5 (cg-RX-API-DMAC7.html)
JP7115758B2 (ja) Ｃｄ１６ａ指向性ｎｋ細胞エンゲージメント用タンデムダイアボディ
CN110662560B (zh) 改进的抗原结合受体
RU2729401C2 (ru) Композиции и способы для иммунотерапии
JP2017531427A5 (cg-RX-API-DMAC7.html)
Geering et al. Synthetic immunology: modulating the human immune system
JP2019535763A (ja) 前立腺特異的膜抗原（ｐｓｍａ）を標的とする三重特異性タンパク質と使用方法
CN108697736A (zh) 治疗性组合物和方法
CN110461357A (zh) 抗cd16a抗体与细胞因子的组合
JP2019511222A5 (cg-RX-API-DMAC7.html)
HRP20241228T1 (hr) T stanični receptori i imunološka terapija uporabom istih protiv pram pozitivnih karcinoma
JP2016505635A5 (cg-RX-API-DMAC7.html)
JP2018517431A (ja) 三重特異性結合タンパク質と使用方法
JP2015528003A5 (cg-RX-API-DMAC7.html)
RU2017115315A (ru) Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
FI3250592T3 (fi) Transtyretiinin vastaisia vasta-aineita
JP2016529229A5 (cg-RX-API-DMAC7.html)
JP7404279B2 (ja) 様々な構築物最適化を備えたｔ細胞抗原カプラ
JP2017536337A5 (cg-RX-API-DMAC7.html)
JP2018505893A5 (cg-RX-API-DMAC7.html)
CN113056283A (zh) 关于治疗血液肿瘤的工程化和非工程化γδ-T细胞的组合物和方法
US20230303660A1 (en) Co-stimulatory 4-1bbl ectodomain polypeptides for immunomodulation
US20230357355A1 (en) Cspg4-targeting humanized chimeric antigen receptor, immune effector cell expressing chimeric antigen receptor, and applications thereof
CN108350069A (zh) 针对il-23的多肽
CN103897057B (zh) 多价抗体片段与其三聚复合物